Schonfeld Strategic Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$24.1M Buy
26,237
+25,811
+6,059% +$26.2M 0.17% 116
2025
Q4
$458K Sell
426
-223,023
-100% -$213M ﹤0.01% 1424
2025
Q3
$18M Buy
223,449
+128,400
+135% +$95.6M 0.1% 209
2025
Q2
$74.1M Buy
95,049
+70,502
+287% +$54.8M 0.5% 20
2025
Q1
$20.3M Buy
24,547
+3,528
+17% +$2.94M 0.12% 166
2024
Q4
$16.2M Buy
21,019
+5,539
+36% +$4.59M 0.09% 187
2024
Q3
$13.7M Buy
15,480
+8,010
+107% +$7.2M 0.09% 223
2024
Q2
$6.76M Sell
7,470
-3,593
-32% -$2.87M 0.04% 473
2024
Q1
$8.61M Buy
11,063
+9,818
+789% +$6.99M 0.06% 428
2023
Q4
$726K Sell
1,245
-74,474
-98% -$43.5M ﹤0.01% 1153
2023
Q3
$40.7M Buy
75,719
+49,593
+190% +$25.6M 0.32% 56
2023
Q2
$12.3M Buy
26,126
+25,826
+8,609% +$10.8M 0.11% 299
2023
Q1
$103K Sell
300
-5,183
-95% -$1.75M ﹤0.01% 1687
2022
Q4
$2.01M Buy
5,483
+1,183
+28% +$419K 0.02% 819
2022
Q3
$1.39M Sell
4,300
-18,321
-81% -$5.8M 0.01% 1066
2022
Q2
$7.33M Buy
+22,621
New +$6.79M 0.07% 354
2022
Q1
Sell
-9,418
Closed -$2.6M 2775
2021
Q4
$2.6M Sell
9,418
-2,152
-19% -$546K 0.02% 635
2021
Q3
$2.67M Sell
11,570
-56,757
-83% -$14M 0.03% 617
2021
Q2
$15.7M Buy
+68,327
New +$13.7M 0.17% 176
2021
Q1
Sell
-23,700
Closed -$4M 1990
2020
Q4
$4M Sell
23,700
-27,329
-54% -$4.08M 0.05% 452
2020
Q3
$7.55M Buy
51,029
+45,709
+859% +$7.07M 0.14% 202
2020
Q2
$873K Buy
+5,320
New +$817K 0.02% 641
2020
Q1
Sell
-4,934
Closed -$648K 1349
2019
Q4
$648K Sell
4,934
-7,970
-62% -$924K 0.02% 649
2019
Q3
$1.44M Buy
12,904
+6,004
+87% +$668K 0.04% 387
2019
Q2
$764K Sell
6,900
-7,571
-52% -$892K 0.03% 519
2019
Q1
$1.88M Buy
+14,471
New +$1.76M 0.07% 355
2017
Q4
Sell
-39,773
Closed -$3.4M 818
2017
Q3
$3.4M Buy
+39,773
New +$3.26M 0.31% 104
2017
Q2
Sell
-75,000
Closed -$6.31M 698
2017
Q1
$6.31M Sell
75,000
-71,398
-49% -$5.72M 0.63% 30
2016
Q4
$10.8M Buy
+146,398
New +$10.9M 1.39% 2

Other funds holding LLY

Schonfeld Strategic Advisors's LLY Position: Q1 2026 in Review

Schonfeld Strategic Advisors increased its Eli Lilly (LLY) stake by 6,059% in Q1 2026, buying an estimated $26.2M and bringing the position to 26,237 shares worth $24.1M. The position accounts for 0.17% of the portfolio, ranked #116.

Schonfeld Strategic Advisors first reported a position in LLY in Q4 2016 and has held it in 29 quarters since. The position peaked at $74.1M in Q2 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Schonfeld Strategic Advisors held 26,237 shares of Eli Lilly worth $24.1M as of Q1 2026.
  • Schonfeld Strategic Advisors bought 25,811 Eli Lilly shares in Q1 2026, an estimated $26.2M.
  • Eli Lilly made up 0.17% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #116 holding.
  • Schonfeld Strategic Advisors first reported a position in Eli Lilly in Q4 2016 and has held it in 29 quarters since.
  • Schonfeld Strategic Advisors's Eli Lilly position peaked at $74.1M in Q2 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.